JP2020507626A - 腸上皮の透過性と関連する疾患を治療する組成物及び方法 - Google Patents

腸上皮の透過性と関連する疾患を治療する組成物及び方法 Download PDF

Info

Publication number
JP2020507626A
JP2020507626A JP2019564370A JP2019564370A JP2020507626A JP 2020507626 A JP2020507626 A JP 2020507626A JP 2019564370 A JP2019564370 A JP 2019564370A JP 2019564370 A JP2019564370 A JP 2019564370A JP 2020507626 A JP2020507626 A JP 2020507626A
Authority
JP
Japan
Prior art keywords
larazotide
derivative
subject
administering
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019564370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507626A5 (https=
Inventor
ジェイ メイダン
ジェイ メイダン
アンソニー ブリクスラガー
アンソニー ブリクスラガー
Original Assignee
イノベイト バイオファーマシューティカルズ インコーポレイテッド
イノベイト バイオファーマシューティカルズ インコーポレイテッド
ノース カロライナ ステート ユニバーシティー
ノース カロライナ ステート ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノベイト バイオファーマシューティカルズ インコーポレイテッド, イノベイト バイオファーマシューティカルズ インコーポレイテッド, ノース カロライナ ステート ユニバーシティー, ノース カロライナ ステート ユニバーシティー filed Critical イノベイト バイオファーマシューティカルズ インコーポレイテッド
Publication of JP2020507626A publication Critical patent/JP2020507626A/ja
Publication of JP2020507626A5 publication Critical patent/JP2020507626A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019564370A 2017-02-10 2018-02-12 腸上皮の透過性と関連する疾患を治療する組成物及び方法 Pending JP2020507626A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457279P 2017-02-10 2017-02-10
US62/457,279 2017-02-10
PCT/US2018/017813 WO2018148655A1 (en) 2017-02-10 2018-02-12 Compositions and methods for treating disease associated with permeability of intestinal epithelium

Publications (2)

Publication Number Publication Date
JP2020507626A true JP2020507626A (ja) 2020-03-12
JP2020507626A5 JP2020507626A5 (https=) 2021-03-25

Family

ID=63107916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019564370A Pending JP2020507626A (ja) 2017-02-10 2018-02-12 腸上皮の透過性と関連する疾患を治療する組成物及び方法

Country Status (11)

Country Link
US (3) US11058902B2 (https=)
EP (2) EP3579862A4 (https=)
JP (1) JP2020507626A (https=)
KR (1) KR20190121785A (https=)
CN (1) CN110891587A (https=)
AU (1) AU2018219367A1 (https=)
BR (1) BR112019016705A2 (https=)
CA (1) CA3052975A1 (https=)
MX (1) MX2019009586A (https=)
WO (2) WO2018148655A1 (https=)
ZA (1) ZA201905439B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11058902B2 (en) * 2017-02-10 2021-07-13 9 Meters Biopharma, Inc. Compositions and methods for treating disease associated with permeability of intestinal epithelium
WO2019165346A1 (en) 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compounds and methods for treating tight junction permeability
US20210100868A1 (en) * 2018-03-19 2021-04-08 North Carolina State University Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy
WO2019183036A1 (en) 2018-03-19 2019-09-26 Innovate Biopharmaceuticals, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
WO2021034629A1 (en) * 2019-08-16 2021-02-25 9 Meters Biopharma, Inc. Larazotide formulations
AU2021255955A1 (en) * 2020-04-15 2022-11-10 Interlude Biopharma Co. Larazotide derivatives comprising d-amino acids
WO2023154770A1 (en) * 2022-02-09 2023-08-17 9 Meters Biopharma, Inc. Compositions and methods for inhibiting rho kinase
CN114788837B (zh) * 2022-06-07 2023-09-05 青岛东海药业有限公司 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543779A (ja) * 2005-06-09 2008-12-04 ユニバーシティ オブ メリーランド， ボルチモア 膵細胞の損失を予防するか、膵細胞を再生するためのゾヌリンのアンタゴニストの使用法
JP2009527468A (ja) * 2006-02-09 2009-07-30 アルバ セラピューティクス コーポレーション タイトジャンクション・エフェクター用製剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665389A (en) 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5945510A (en) 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
AU2001249067A1 (en) 2000-05-19 2001-12-03 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
US20060062758A1 (en) * 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
US20090176244A1 (en) 2005-05-13 2009-07-09 Bai Julio Methods and compositions for the diagnosis of crohn's disease
CN101189518A (zh) * 2005-05-13 2008-05-28 马里兰巴尔的摩大学 评价治疗方案有效性的方法
WO2008043107A2 (en) 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20110201543A1 (en) 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
WO2009052489A2 (en) 2007-10-19 2009-04-23 Alba Therapeutics Corporation Novel inhibitors of mammalian tight junction opening
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
CN101440369A (zh) * 2008-03-26 2009-05-27 华东师范大学 一种缺失的霍乱弧菌封闭带毒素的表达方法及应用
WO2009137572A2 (en) * 2008-05-06 2009-11-12 Alba Therapeutics Corporation Inhibition of gliadin peptides
WO2010042821A1 (en) * 2008-10-10 2010-04-15 Nationwide Children's Hospital Method of treating necrotizing enterocolitis using heparin binding epidermal growth factor
EP3125870A4 (en) * 2014-04-04 2017-12-13 Alba Therapeutics Corporation Methods of treating celiac disease with larazotide
CA2955425A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
US11058902B2 (en) * 2017-02-10 2021-07-13 9 Meters Biopharma, Inc. Compositions and methods for treating disease associated with permeability of intestinal epithelium

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543779A (ja) * 2005-06-09 2008-12-04 ユニバーシティ オブ メリーランド， ボルチモア 膵細胞の損失を予防するか、膵細胞を再生するためのゾヌリンのアンタゴニストの使用法
JP2009527468A (ja) * 2006-02-09 2009-07-30 アルバ セラピューティクス コーポレーション タイトジャンクション・エフェクター用製剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DAMMS-MACHADO, A. ET AL.: "Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese ind", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 105, no. 1, JPN6021048102, January 2017 (2017-01-01), pages 127 - 135, ISSN: 0004657208 *
GOPALAKRISHNAN, S. ET AL.: "Larazotide acetate regulates epithelial tight junctions in vitro and in vivo", PEPTIDES, vol. 35, no. 1, JPN6021048114, 2012, pages 86 - 94, ISSN: 0004657205 *
MIELE, L. ET AL.: "Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target", CURRENT PHARMACEUTICAL DESIGN, vol. 19, no. 29, JPN6021048110, 2013, pages 5314 - 5324, ISSN: 0004657206 *
MIELE, L. ET AL.: "Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease", HEPATOLOGY, vol. 49, no. 6, JPN6021048101, 2009, pages 1877 - 1887, ISSN: 0004657209 *
SCARPELLINI, E. ET AL.: "Intestinal permeability in non-alcoholic fatty liver disease: the gut-liver axis", REVIEWS ON RECENT CLINICAL TRIALS, vol. 9, no. 3, JPN6021048105, 2014, pages 141 - 147, ISSN: 0004657207 *
STURGEON, C., FASANO, A.: "Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic", TISSUE BARRIERS, vol. 4, no. 4, JPN6021048116, 2016, pages 1251384, ISSN: 0004881664 *

Also Published As

Publication number Publication date
US20210299481A1 (en) 2021-09-30
EP3579862A1 (en) 2019-12-18
CN110891587A (zh) 2020-03-17
WO2018148655A1 (en) 2018-08-16
CA3052975A1 (en) 2018-08-16
ZA201905439B (en) 2021-02-24
EP3579863A4 (en) 2020-11-11
MX2019009586A (es) 2019-11-11
US20190358288A1 (en) 2019-11-28
BR112019016705A2 (pt) 2020-04-07
EP3579863A1 (en) 2019-12-18
US20190358289A1 (en) 2019-11-28
US11058902B2 (en) 2021-07-13
WO2018148654A1 (en) 2018-08-16
AU2018219367A1 (en) 2019-09-19
KR20190121785A (ko) 2019-10-28
EP3579862A4 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
US11058902B2 (en) Compositions and methods for treating disease associated with permeability of intestinal epithelium
JP6464142B2 (ja) プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー
JP2019504887A (ja) 経口コレスチラミン製剤及びその使用
JP6895752B2 (ja) ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物
TR201809416T4 (tr) Bir gecikmeli salım ilaç formülasyonu.
JPWO1995028963A1 (ja) 結腸特異的薬物放出システム
CN117398392A (zh) 一种调节肠道微生物群的治疗方法
US20190262407A1 (en) Probiotic compositions and methods of use thereof
JP2011500552A (ja) 胃腸障害を処置するための医薬用組み合わせおよび組成物
WO2019199642A1 (en) Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage
JP6554468B2 (ja) ニコチンアミドと５−アミノサリチル酸との組合せを含有する、腸内微生物叢に有益な影響を及ぼすため、かつ／または胃腸の炎症を処置するため
CN114514031A (zh) 拉拉唑肽制剂
JP7700109B2 (ja) 胃腸の健康組成物
KR20170122776A (ko) 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약
US20210100868A1 (en) Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy
US20230218706A1 (en) Larazotide derivatives comprising d-amino acids
Newton et al. IBD–impact of colonic pH, onset of action and other factors in modern therapeutic approach
Sans Probiotics for inflammatory bowel disease: a critical appraisal
RU2812928C2 (ru) Твердая композиция для доставки
HK40012186A (en) Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CA2974055A1 (en) A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk forintestinal bacterial translocation
HK40000727A (en) Treatment for modulating gut microbiota
WO2013186191A1 (en) Formulations of metronidazole for the treatment of pouchitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191001

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20191001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220927